© 2004 by Oxford University Press
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
© 2004 Oxford University Press
ARTICLE |
Conventional Adjuvant Chemotherapy Versus Single-Cycle, Autograft-Supported, High-Dose, Late-Intensification Chemotherapy in High-Risk Breast Cancer Patients: A Randomized Trial
For the Anglo-Celtic Cooperative Oncology Group
Affiliations of authors: South West Wales Cancer Institute and University of Wales, Swansea (RCFL); Academic Department of Oncology, University of Hull, Hull, England (ML); Cancer Research UK Cancer Research Unit, University of Bradford, Bradford, England (CT); Weston Park Hospital and University of Sheffield, Sheffield, England (RC); University Hospital of Ghent, Ghent, Belgium (SVB); Addenbrookes Hospital, Cambridge, England (CW); University College, London, England (JL); Waikito Hospital, Waikito, New Zealand (IK); Velindre NHS Trust and Welsh School of Pharmacy, Cardiff, Wales (PBL); St. James's University Hospital, Leeds, England (TP); Northern Institute for Cancer Research, Newcastle upon Tyne, England (MV); Western General Hospital and Edinburgh University, Edinburgh, Scotland (DC); Scottish Cancer Therapy Network, Edinburgh (LF); Quantics Consulting Limited, Edinburgh (AY); St. Vincent's University Hospital, Dublin, Ireland (JC)
Correspondence to: R. C. F. Leonard, MD, South West Wales Cancer Institute, Singleton Hospital, Swansea, Wales, U.K. SA2 8QA (e-mail: r.c.f.leonard{at}swan.ac.uk)
Background: Breast cancer patients with four or more positive axillary lymph nodes who are treated with conventional adjuvant therapy have a poor prognosis. In uncontrolled studies, high-dose chemotherapy produced much better results than conventional therapy. We compared the benefits of a single cycle of high-dose chemotherapy and the benefits of conventional chemotherapy in patients with high-risk breast cancer in a prospective, unblinded, randomized trial. Methods: Between February 23, 1995, and June 29, 1999, 605 patients with breast cancer who had four or more positive lymph nodes were randomly assigned to treatment (307 to high-dose therapy and 298 to conventional therapy). The conventional chemotherapy regimen was four cycles of doxorubicin (75 mg/m2) followed by eight cycles of CMF (cyclophosphamide [600 mg/m2], methotrexate [50 mg/m2], and 5-fluorouracil [600 mg/m2]), all given intravenously on day 1 of a 21-day cycle. The high-dose regimen was four cycles of doxorubicin (75 mg/m2), followed by a single cycle of intermediate-dose cyclophosphamide (4000 mg/m2) supported by filgrastim (300 µg/day) for up to 10 days followed by high-dose cyclophosphamide (6000 mg/m2) and thiotepa (800 mg/m2). Peripheral blood progenitor cells were harvested by leukapheresis after treatment with cyclophosphamide and filgrastim and then re-infused after the high-dose cycle. Log-rank tests were used to compare survival rates. All statistical analyses were two-sided. Results: At a median follow-up of 6 years, no statistically significant differences were detected between the arms in 5-year relapse-free survival (high-dose arm = 57%, 95% confidence interval [CI] = 51% to 63%; conventional-dose arm = 54%, 95% CI = 48% to 61% (P = .73) or in 5-year overall survival (high-dose arm = 62%, 95% CI = 56% to 68%; conventional-dose arm = 64%, 95% CI = 57% to 70%) (P = .38). Conclusion: Autograft-supported, high-dose therapy is not superior to conventional chemotherapy in patients with breast cancer who have multiple involved lymph nodes. This conclusion should be viewed in the context of improving the success of conventional chemotherapy.
CiteULike 
Connotea 
Del.icio.us What's this?
Related Memo to the Media
- Press Release: High-Dose Chemotherapy Not Superior to Conventional Chemotherapy in High-Risk Breast Cancer Patients
- Sarah L. Zielinski
J Natl Cancer Inst 2004 96: 1047.[Extract] [Full Text]
This article has been cited by other articles:
|
|
 |
|
  A. R. Zander, C. Schmoor, N. Kroger, W. Kruger, V. Mobus, N. Frickhofen, B. Metzner, W. E. Berdel, M. Koenigsmann, E. Thiel, et al. Randomized trial of high-dose adjuvant chemotherapy with autologous hematopoietic stem-cell support versus standard-dose chemotherapy in breast cancer patients with 10 or more positive lymph nodes: overall survival after 6 years of follow-up Ann. Onc., June 1, 2008; 19(6): 1082 - 1089. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
O. Gluz, U. A. Nitz, N. Harbeck, E. Ting, R. Kates, A. Herr, W. Lindemann, C. Jackisch, W. E. Berdel, H. Kirchner, et al. Triple-negative high-risk breast cancer derives particular benefit from dose intensification of adjuvant chemotherapy: results of WSG AM-01 trial Ann. Onc., May 1, 2008; 19(5): 861 - 870. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Nieto, F. Nawaz, R. B. Jones, E. J. Shpall, and S. Nawaz Prognostic Significance of Overexpression and Phosphorylation of Epidermal Growth Factor Receptor (EGFR) and the Presence of Truncated EGFRvIII in Locoregionally Advanced Breast Cancer J. Clin. Oncol., October 1, 2007; 25(28): 4405 - 4413. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. C.F. Moore, S. J. Green, J. R. Gralow, S. I. Bearman, D. Lew, W. E. Barlow, C. Hudis, A. C. Wolff, J. N. Ingle, H. K. Chew, et al. Intensive Dose-Dense Compared With High-Dose Adjuvant Chemotherapy for High-Risk Operable Breast Cancer: Southwest Oncology Group/Intergroup Study 9623 J. Clin. Oncol., May 1, 2007; 25(13): 1677 - 1682. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N Wilking, E Lidbrink, T Wiklund, B Erikstein, H Lindman, P Malmstrom, P Kellokumpu-Lehtinen, N-O Bengtsson, G Soderlund, G Anker, et al. Long-term follow-up of the SBG 9401 study comparing tailored FEC-based therapy versus marrow-supported high-dose therapy Ann. Onc., April 1, 2007; 18(4): 694 - 700. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. J. Poole, H. M. Earl, L. Hiller, J. A. Dunn, S. Bathers, R. J. Grieve, D. A. Spooner, R. K. Agrawal, I. N. Fernando, A. M. Brunt, et al. Epirubicin and Cyclophosphamide, Methotrexate, and Fluorouracil as Adjuvant Therapy for Early Breast Cancer N. Engl. J. Med., November 2, 2006; 355(18): 1851 - 1862. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
International Breast Cancer Study Group Multicycle Dose-Intensive Chemotherapy for Women With High-Risk Primary Breast Cancer: Results of International Breast Cancer Study Group Trial 15-95 J. Clin. Oncol., January 20, 2006; 24(3): 370 - 378. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. C. Coombes, A. Howell, M. Emson, C. Peckitt, C. Gallagher, C. Bengala, A. Tres, R. Welch, P. Lawton, R. Rubens, et al. High dose chemotherapy and autologous stem cell transplantation as adjuvant therapy for primary breast cancer patients with four or more lymph nodes involved: long-term results of an international randomised trial Ann. Onc., May 1, 2005; 16(5): 726 - 734. [Abstract] [Full Text] [PDF]
|
|